The SUNDAY Trial is a randomized, open-label, observer-blinded, two-armed controlled study that addresses the question of whether thoracic endovascular aortic repair (TEVAR) impacts five-year survival among patients with an uncomplicated Stanford type-B aortic dissection.

It is investigator-driven, and patients will be randomized to either standard medical therapy (SMT) alone or SMT + subacute TEVAR. The primary outcome is five-year survival, while secondary outcomes include aortic-related mortality, neurological events, quality of life, costs, reinterventions and readmissions. In addition, subgroup analyses based on the extent of aortic treatment will be investigated.